repaglinide has been researched along with itraconazole in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (33.33) | 29.6817 |
| 2010's | 9 (60.00) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Dalvie, D; Loi, CM; Smith, DA | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Backman, JT; Neuvonen, M; Neuvonen, PJ; Niemi, M | 1 |
| Backman, JT; Kajosaari, LI; Laitila, J; Neuvonen, PJ | 1 |
| Bode, C | 1 |
| Chen, W; Gan, J; Gao, L; Hong, Y; Humphreys, WG; Li, W; Rodrigues, AD; Shen, H; Tang, Y; Tian, Y; Zhang, H; Zhang, Y | 1 |
| Hisaka, A; Ito, K; Kudo, T; Sugiyama, Y | 1 |
| Furihata, KI; Kusuhara, H; Maeda, K; Sugiyama, Y; Yoshikado, T | 1 |
| Ito, S; Iwamoto, K; Kamimura, H; Mizunaga, M; Nakayama, K; Negoro, T; Nishiwaki, M; Nomura, Y; Suemizu, H; Yamazaki, H; Yoneda, N | 1 |
2 review(s) available for repaglinide and itraconazole
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
The nasty surprise of a complex drug-drug interaction.
Topics: Carbamates; Drug Approval; Drug Evaluation, Preclinical; Drug Industry; Drug Interactions; Drug Therapy, Combination; Gemfibrozil; Humans; Itraconazole; Models, Biological; Piperidines | 2010 |
1 trial(s) available for repaglinide and itraconazole
| Article | Year |
|---|---|
Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide.
Topics: Adult; Antifungal Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Biotransformation; Blood Glucose; C-Peptide; Carbamates; Cross-Over Studies; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Gemfibrozil; Half-Life; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Itraconazole; Male; Piperidines | 2003 |
12 other study(ies) available for repaglinide and itraconazole
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin.
Topics: Aryl Hydrocarbon Hydroxylases; Bezafibrate; Carbamates; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Fenofibrate; Gemfibrozil; Humans; Hypoglycemic Agents; In Vitro Techniques; Itraconazole; Microsomes, Liver; Midazolam; Paclitaxel; Piperidines; Quercetin; Rifampin | 2005 |
Repaglinide-gemfibrozil drug interaction: inhibition of repaglinide glucuronidation as a potential additional contributing mechanism.
Topics: Biotransformation; Carbamates; Cells, Cultured; Dose-Response Relationship, Drug; Drug Interactions; Gemfibrozil; Glucuronides; Glucuronosyltransferase; Hepatocytes; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Itraconazole; Microsomes, Liver; Piperidines | 2010 |
Analysis of the repaglinide concentration increase produced by gemfibrozil and itraconazole based on the inhibition of the hepatic uptake transporter and metabolic enzymes.
Topics: Area Under Curve; Aryl Hydrocarbon Hydroxylases; Biotransformation; Carbamates; Computer Simulation; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Enzyme Inhibitors; Gemfibrozil; Glucuronides; Humans; Hypoglycemic Agents; Itraconazole; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Biological; Nonlinear Dynamics; Organic Anion Transporters; Piperidines | 2013 |
Quantitative Analyses of the Influence of Parameters Governing Rate-Determining Process of Hepatic Elimination of Drugs on the Magnitudes of Drug-Drug Interactions via Hepatic OATPs and CYP3A Using Physiologically Based Pharmacokinetic Models.
Topics: Adult; Bosentan; Carbamates; Computer Simulation; Cytochrome P-450 CYP3A; Drug Interactions; Hepatobiliary Elimination; Humans; Itraconazole; Liver; Male; Models, Biological; Organic Anion Transporters; Pharmaceutical Preparations; Piperidines; Rifampin; Sulfonamides; Young Adult | 2017 |
Predicted values for human total clearance of a variety of typical compounds with differently humanized-liver mouse plasma data.
Topics: Acetamides; Albuterol; Animals; Carbamates; Chromatography, Liquid; Diazepam; Diclofenac; Digitoxin; Humans; Itraconazole; Ketoprofen; Liver; Metabolic Clearance Rate; Mice; Mice, Transgenic; Naproxen; Pharmaceutical Preparations; Phenytoin; Piperidines; Pravastatin; Pyrimidines; Quinidine; Tandem Mass Spectrometry; Telmisartan; Terfenadine; Verapamil | 2020 |